C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies
Marco Moschini,Shahrokh F. Shariat,Shahrokh F. Shariat,Shahrokh F. Shariat,Morgan Rouprêt,Maria De Santis,Maria De Santis,Joaquim Bellmunt,Cora N. Sternberg,Bertrand Tombal,Laurence Collette +10 more
TL;DR: Primary tumor location had no impact on progression‐free or overall survival in patients with locally advanced or metastatic urothelial carcinoma treated with platinum based combination chemotherapy.
Journal Article
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey.
Andrea Mancuso,S. Sacchetta,P. Saletti,C. Tronconi,L. Milesi,Marina Chiara Garassino,Olga Martelli,Alvaro Leone,Andrea Zivi,Linda Cerbone,Federica Recine,R. Sollami,R. Labianca,F. Cavalli,Cora N. Sternberg +14 more
TL;DR: In this article, a retrospective multicenter study was performed to evaluate the efficacy of salvage treatment with the hypothesis that levels of the DNA repair gene excision repair cross complementing 1 (ERCC1) could influence overall survival.
Journal ArticleDOI
Advances in the Treatment of Urothelial Tract Tumors
TL;DR: Recently developed combination chemotherapy programs have now produced durable complete remissions in a significant percentage of patients with advanced urothelial tract malignancies, and the goal of individualized therapies may soon be possible, which will ideally translate into increased clinical benefit for patients with urothalial tract tumors.
Journal ArticleDOI
Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
TL;DR: The management of advanced castration resistant prostate cancer (CRPC) has been rapidly changing and is still evolving.
Journal ArticleDOI
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis
Anuradha Jayaram,Anna Wingate,Daniel Wetterskog,Vincenza Conteduca,Daniel Khalaf,Mansour T. A. Sharabiani,Fabio Calabrò,Lorraine Barwell,Susan Feyerabend,Enrique Grande,Alberto Martínez-Carrasco,Albert Font,Alfredo Berruti,Cora N. Sternberg,Robert Jones,Florence Lefresne,Marjolein Lahaye,Shibu Thomas,Shilpy Joshi,Dong Shen,Deborah Ricci,Michael Gormley,Axel S. Merseburger,Bertrand Tombal,Matti Annala,Matti Annala,Kim N. Chi,Kim N. Chi,Ugo De Giorgi,Enrique Gonzalez-Billalabeitia,Alexander W. Wyatt,Gerhardt Attard +31 more
TL;DR: Patients with metastatic castration-resistant prostate cancer can be dichotomized by a plasma AR CN cut point of 1.92 or greater that identifies aggressive disease that is poorly responsive to AR targeting and is associated with a prior short response to primary androgen-deprivation therapy.